Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 30.98% | 41.91% | 34.46% | 17.25% | 8.91% |
| Total Depreciation and Amortization | 83.87% | 44.74% | 43.24% | -38.89% | -11.43% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 140.19% | 150.97% | 112.88% | 1.57% | -23.79% |
| Change in Net Operating Assets | 182.57% | -85.46% | -73.34% | -69.30% | -79.39% |
| Cash from Operations | 55.39% | 46.31% | 42.84% | 9.07% | -8.67% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -52.38% | 5.00% | -30.00% | -72.50% | -30.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 92.88% | 367.16% | 346.21% | 987.50% | -73.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -35.33% | 25.93% | -15.22% | -62.63% | -41.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.76% | 141.43% | 124.67% | -331.93% | -254.97% |